{Reference Type}: Journal Article
{Title}: Type 2 severe asthma: pathophysiology and treatment with biologics.
{Author}: Pelaia C;Melhorn J;Hinks TS;Couillard S;Vatrella A;Pelaia G;Pavord ID;
{Journal}: Expert Rev Respir Med
{Volume}: 18
{Issue}: 7
{Year}: 2024 Jul 23
{Factor}: 4.3
{DOI}: 10.1080/17476348.2024.2380072
{Abstract}: <B>UNASSIGNED: </B>The hallmark of most patients with severe asthma is type 2 inflammation, driven by innate and adaptive immune responses leading to either allergic or non-allergic eosinophilic infiltration of airways. The cellular and molecular pathways underlying severe type 2 asthma can be successfully targeted by specific monoclonal antibodies.<BR><B>UNASSIGNED: </B>This review article provides a concise overview of the pathophysiology of type 2 asthma, followed by an updated appraisal of the mechanisms of action and therapeutic efficacy of currently available biologic treatments used for management of severe type 2 asthma. Therefore, all reported information arises from a wide literature search performed on PubMed.<BR><B>UNASSIGNED: </B>The main result of the recent advances in the field of anti-asthma biologic therapies is the implementation of a personalized medicine approach, aimed to achieve clinical remission of severe asthma. Today this accomplishment is made possible by the right choice of the most beneficial biologic drug for the pathologic traits characterizing each patient, including type 2 severe asthma and its comorbidities.